RxDoctor Payments Data

Roxana Vega, PA

Physician Assistant · New York, NYNPI 1124274204

Payments from drug & device makers

$2,816in general payments, 2019–2025

Across 79 payments — averaging $35.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$379
  • Merck$376
  • Novartis$321
  • Amgen$218
  • Novo Nordisk$196
  • Cvrx, Inc.$180
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,78499%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,816 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$3,102
Medicare patients
26
Services billed
38

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$55,821
XareltoRivaroxaban33$45,980
Repatha SureclickEvolocumab56$40,930
EntrestoSacubitril/Valsartan18$21,610
Praluent PenAlirocumab14$10,365
Ranolazine ErRanolazine33$4,568
EdarbyclorAzilsartan Med/Chlorthalidone13$3,196
Isosorbide Mononitrate ErIsosorbide Mononitrate180$2,865
Olmesartan Medoxomil50$2,408
Rosuvastatin Calcium68$1,912
Metoprolol Succinate142$1,737
Labetalol Hcl41$1,045
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$975
Hydralazine Hcl50$861
Digoxin23$859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$55,82144 claims
Johnson & JohnsonXarelto$140$45,98033 claims
NovartisEntresto$321$21,61018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →